Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) just unveiled an update.
Cosmo Pharmaceuticals N.V. has launched Winlevi®, a novel acne treatment, in Singapore and Malaysia, marking its first entry into the Southeast Asian market through a partnership with Hyphens Pharma International Limited. This launch represents a significant step in Cosmo’s global expansion strategy, aiming to meet the unmet needs of patients with acne vulgaris, a common skin condition affecting millions worldwide. The collaboration with Hyphens Pharma underscores both companies’ commitment to providing innovative dermatological solutions and expanding their presence in a rapidly growing market.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a global leader in AI-powered healthcare and specialty pharmaceuticals, focusing on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing. The company is known for designing, developing, and manufacturing advanced solutions that address critical medical needs, improving the standard of care worldwide. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in the USA and Italy.
Average Trading Volume: 24,248
Current Market Cap: CHF1.03B
For detailed information about COPN stock, go to TipRanks’ Stock Analysis page.